Renaissance Technologies LLC Trims Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Renaissance Technologies LLC reduced its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 7.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 545,021 shares of the biotechnology company's stock after selling 44,059 shares during the period. Renaissance Technologies LLC owned 0.26% of BioCryst Pharmaceuticals worth $4,099,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of BCRX. Xponance Inc. boosted its position in BioCryst Pharmaceuticals by 9.1% during the fourth quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company's stock worth $112,000 after acquiring an additional 1,242 shares during the last quarter. Sei Investments Co. grew its position in shares of BioCryst Pharmaceuticals by 2.8% in the fourth quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company's stock valued at $430,000 after purchasing an additional 1,537 shares during the period. SkyView Investment Advisors LLC increased its stake in BioCryst Pharmaceuticals by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 3,000 shares during the last quarter. Arizona State Retirement System lifted its position in BioCryst Pharmaceuticals by 6.6% during the fourth quarter. Arizona State Retirement System now owns 57,001 shares of the biotechnology company's stock worth $429,000 after buying an additional 3,518 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in BioCryst Pharmaceuticals by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 43,920 shares of the biotechnology company's stock worth $330,000 after buying an additional 4,129 shares during the period. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BCRX has been the subject of a number of research analyst reports. Evercore ISI upped their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. Royal Bank of Canada reiterated an "outperform" rating and issued a $11.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, April 11th. HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Wedbush assumed coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 target price on the stock. Finally, JMP Securities reissued a "market outperform" rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.57.

BioCryst Pharmaceuticals Trading Up 2.1 %

Shares of BCRX traded up $0.17 during midday trading on Friday, reaching $8.39. 3,208,207 shares of the company were exchanged, compared to its average volume of 2,803,998. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.11 and a 1-year high of $9.50. The stock has a 50-day moving average price of $7.72 and a 200-day moving average price of $7.75. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -13.75 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analysts' expectations of $126.64 million. The firm's revenue for the quarter was up 40.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.28 EPS. Equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.